Dupilumab in chronic obstructive pulmonary disease

Drug and Therapeutics Bulletin 2026 Open access

Read full text
Authors: BMJ Publishing Group Ltd
DOI: 10.1136/dtb.2026.000013
Cited by: 1
References: 20

Abstract

DTB DRUG REVIEWor one severe exacerbation and blood eosinophils ≥300 cells/ µL, biologic therapy may be used, aiming to block type 2 inflammation.1 5

Fields of Study & Subjects

Chronic Obstructive Pulmonary Disease (COPD) Research Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Drug and Therapeutics Bulletin
Publisher
BMJ
Volume
64
Issue
7
Pages
103–107
Publication date
27 May 2026
Language
EN